Camrelizumab: all 354 studies that test it
Page 1 of 4. Open to participants first (126), then studies with results posted, then the rest; newest registration first within each.
- A Prospective, Single-Arm, Open-Label Clinical Study of the Efficacy and Safety of Hepatic Arterial Infusion Chemotherapy Combined With Targeted Therapy and a PD-1 Inhibitor in Patients With Postoperative Hepatocellular Carcinoma and Microvascular InvasionNot yet recruitingNCT07790419Phase 4
- Interferon Gamma Plus Camrelizumab as Neoadjuvant Therapy for Locally Advanced Esophageal Squamous Cell CarcinomaRecruitingNCT07787273Phase 2
- Camrelizumab With Famitinib for Patients With Rare Head and Neck MalignanciesRecruitingNCT07662681Phase 1/2
- Precision Medicine for Immunotherapy-Resistant Advanced Esophageal CancerNot yet recruitingNCT07653451Phase 2/3
- Multi-Omics-Based Phase Ⅱ Trial of Trastuzumab Rezetecan Plus Camrelizumab for Perioperative Therapy in HER2-Positive Muscle-Invasive Urothelial CarcinomaNot yet recruitingNCT07639983Phase 2
- Camrelizumab Combined With Famitinib Malate and Chemotherapy for Treatment of Recurrent/ Metastatic Cervical CancerNot yet recruitingNCT07627620Phase 2
- A Multicenter, Randomized, Open-label, Controlled Study of HAIC Combined With Camrelizumab and Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular Carcinoma With High-risk Recurrence FactorsNot yet recruitingNCT07618546Not applicable
- Short-Course Definitive Chemoradiotherapy Combined With Adjuvant or Concurrent Plus Adjuvant Camrelizumab for Locally Advanced Unresectable Esophageal Squamous Cell CarcinomaRecruitingNCT07530094Phase 2
- A Single-arm Phase II Clinical Study of Camrelizumab Combined With Long-course Chemoradiotherapy for Total Neoadjuvant Therapy in Locally Advanced Low pMMR/MSS Rectal CancerRecruitingNCT07527026Phase 2
- Short-Course Radiotherapy, Nal-IRI, Capecitabine, and Camrelizumab for Locally Advanced MSS Rectal CancerNot yet recruitingNCT07521605Phase 2
- Camrelizumab, Chemotherapy and Ivarmacitinib in Patients With Resectable Esophageal Squamous Cell CarcinomaRecruitingNCT07505186Phase 2
- A Single-arm, Multicenter, Phase II Clinical Study of Camrelizumab Combined With Famitinib in Adjuvant Therapy After Radical Resection of Cervical CancerNot yet recruitingNCT07466901Not applicable
- Camrelizumab Combined With EGFR Monoclonal Antibody or Chemotherapy for Perioperative Treatment of Locally Advanced Head and Neck Squamous Cell CarcinomaNot yet recruitingNCT07432087Phase 3
- Neoadjuvant Chemoimmunotherapy (Camrelizumab + Paclitaxel + Carboplatin) for Resectable HNSCCNot yet recruitingNCT07400094Phase 2
- A Study of Yttrium [90Y] Microsphere Injection in Combination With Targeted Immunotherapy in the Treatment of HCCRecruitingNCT07334483Phase 2
- Carilizumab and Albumin Paclitaxel for Second-line Treatment of Advanced Gastric CancerRecruitingNCT07320586Phase 2
- FAD Subtype-Guided Combination Therapy for Unresectable Hepatocellular CarcinomaNot yet recruitingNCT07314372Phase 2
- Dalpiciclib Plus Camrelizumab for HCC Patients Who Have Previously Received ICI TreatmentRecruitingNCT07238881Phase 2
- Combination of Carilizumab, Apatinib, and Radiotherapy for Advanced Mucosal MelanomaNot yet recruitingNCT07236528Phase 2
- Neoadjuvant Camrelizumab With Palbociclib for Resectable Esophageal Squamous Cell CarcinomaNot yet recruitingNCT07191977Phase 2
- A Prospective, Randomized, Parallel Trial of Famitinib Malate at Different Doses Combined With Camrelizumab for the Treatment of Recurrent and Metastatic Cervical CancerNot yet recruitingNCT07143292Phase 2
- Camrelizumab in Combination With Chemotherapy as Neoadjuvant Treatment in Patients With Early or Locally Advanced Triple-negative Breast CancerNot yet recruitingNCT07107217Phase 2
- HAIC Combined With Camrelizumab Plus Rivoceranib for Advanced Mixed Hepatocellular-cholangiocarcinoma (HCC-CCA)RecruitingNCT07105748Phase 2
- Tauroursodeoxycholic Acid (TUDCA) Plus Camrelizumab and Regorafenib in Hepatocellular Carcinoma Previously Treated With Anti-PD1/PD-L1 and BevacizumabRecruitingNCT07100392Phase 2
- Short Course Radiotherapy Followed by CAPOX and Carrilizumab and Bevacizumab or Cetuximab for the Initial Treatment of Unresectable Metastatic Rectal CancerNot yet recruitingNCT07059949Phase 2
- Camrelizumab and Chemotherapy With or Without Anlotinib as First-line Treatment for Advanced Gallbladder Cancer and Extrahepatic CholangiocarcinomaEnrolling by invitationNCT06901622Phase 2
- Phase III Trial of Camrelizumab+Apatinib+Eribulin vs. Physician's Choice Chemotherapy in Advanced Triple-Negative Breast CancerRecruitingNCT06889688Phase 3
- A Multicenter Phase II Clinical Study of Neoadjuvant Use of Camrelizumab in Combination With Chemotherapy for Organ Preservation in Esophageal CancerRecruitingNCT06869226Phase 2
- HIM Typing Guides the Treatment of Advanced First-Line Triple-Negative Breast CancerNot yet recruitingNCT06849492Phase 2
- PD-1 Antibody Carilizumab Combined with Apatinib for Unresectable Stage III and IV DMMR Gastric CancerRecruitingNCT06792162Phase 2
- Metronomic Capecitabine with Camrelizumab and Apatinib Mesylate for Treatment of Advanced Pancreatic CancerNot yet recruitingNCT06759090Phase 2
- A Prospective, Randomized, Open, Phase II Clinical Study of Chidamide in Combination with Camrelizumab and Apatinib for Advanced Esophageal CancerNot yet recruitingNCT06745193Phase 2
- First-line Treatment of Advanced/unresectable DDLPSNot yet recruitingNCT06694324Phase 2
- Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGSNot yet recruitingNCT06692491Phase 2
- Clinical Efficacy Study of PD-1 Inhibitor Combined With Neoadjuvant Chemotherapy in Advanced Endometrial CancerRecruitingNCT06561308Phase 2
- A Study of Camrelizumab Plus Apatinib as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Radical Resection or AblationNot yet recruitingNCT06546280Phase 2
- A Single Arm Clinical Study of Dendritic Cell Vaccine Loaded With Circular RNA Encoding Cryptic Peptide for Patients With HER2-negative Advanced Breast CancerNot yet recruitingNCT06530082Phase 1
- Neoadjuvant Treatment of gBRCA-Mutated HER2-Negative Breast Cancer With HRS-1167 and Famitinib ± CamrelizumabRecruitingNCT06516289Phase 2
- Hypofractionated Radiotherapy +Chemotherapy+ Camrelizumab as Neoadjuvant Therapy for Pancreatic CancerRecruitingNCT06435260Phase 2
- Fruquintinib Plus Camrelizumab and HAIC in the Treatment of Non-MSI-H Advanced Colorectal CancerNot yet recruitingNCT06423937Phase 2
- A Single-arm Phase II Clinical Study of the Efficacy and Safety of Camrelizumab Combined With GEMOX for Unresectable GBCsRecruitingNCT06423170Phase 2
- Linperlisib Combined With Camrelizumab and Pegaspargase in Advanced or Relapsed/Refractory NK/T-cell LymphomaRecruitingNCT06376721Phase 1/2
- A Study of TAE+HAIC Combined With Camrelizumab and Apatinib in the Treatment of Advanced Hepatocellular CarcinomaRecruitingNCT06363825Phase 2
- Anti-PD-1/PD-L1 Combined With Anti-angiogenic Agents as First-line Treatment for Unresectable HCCRecruitingNCT06360042Phase 2
- Treatment of Rectal Cancer With Long-term Concurrent Chemoradiotherapy Combined With CamrelizumabNot yet recruitingNCT06304545Phase 2
- Neoadjuvant Chemotherapy Plus Camrelizumab for FIGO Stage IB1 Cervical CancerRecruitingNCT06289062Phase 2
- Neoadjuvant Chemoimmunotherapy Versus Concurrent Chemoradiotherapy for LACCRecruitingNCT06288373Phase 2/3
- Neoadjuvant Immunochemotherapy in PD-L1-negative LACCRecruitingNCT06288360Phase 2
- A Study of Camrelizumab Combined With Chemotherapy ± Thalidomide in First-line Treatment of Patients With Advanced Non-small Cell Lung Cancer (NSCLC)Not yet recruitingNCT06276933Phase 4
- Neoadjuvant Camrelizumab Combined With Chemotherapy for Resectable Stage IIIA-IIIB NSCLCRecruitingNCT06241807Phase 2
- Thalidomide Prevention or Treatment of Camrelizumab-induced Reactive Cutaneous Capillary Endothelial Proliferation (RCCEP)RecruitingNCT06231680Phase 2
- Oncolytic Virus Plus PD-1 Inhibitor to Patients With Advanced Pancreatic CancerNot yet recruitingNCT06196671Phase 2
- Efficacy and Safety of Combined With Immunotherapy After Induction Therapy With Chemotherapy and Targeted Therapy in the First-line Treatment of Microsatellite Stable (MSS) Initially Unresectable Metastatic Colorectal CancerRecruitingNCT06176885Phase 2
- Advanced First-line Treatment of Short-term Postoperative Progression of Head and Neck Squamous Cell CarcinomaRecruitingNCT06170697Phase 2
- Camrelizumab Combined With Chemotherapy and Radiotherapy Perioperative Treatment of Esophageal Gastric Junction AdenocarcinomaRecruitingNCT06163729Phase 2
- Fruquintinib Plus Camrelizumab and Capecitabine as Salvage Therapy After Progression on FOLFOXIRI-based First-line Treatment in Patients With Unresectable/Metastatic Colorectal CancerRecruitingNCT06148402Phase 2
- Apatinib Combined With Camrelizumab in Treating Participants With Advanced ChordomaRecruitingNCT06140732Phase 2
- Clinical Study of VG161 Combined With Camrelizumab in Patients With Advanced Primary Hepatocellular CarcinomaNot yet recruitingNCT06124001Phase 1/2
- Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast CancerRecruitingNCT06121557Phase 1
- bTAE-HAIC Combined With System Therapy for Intermediate-advanced Huge HCCRecruitingNCT06061276Not applicable
- Carrelizumab Combined With Concurrent Radiotherapy and Chemotherapy for Unresectable Esophageal Squamous Cell CarcinomaEnrolling by invitationNCT06048926Not applicable
- A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BCTOP-T-N01)RecruitingNCT05999149Phase 3
- Adebrelimab, Camrelizumab Plus Apatinib as First-line Therapy in Patients With Advanced Hepatocellular CarcinomaRecruitingNCT05924997Phase 1/2
- A Multi-center, Randomized, Open-label, Phase III Study Comparing PD-1 Inhibitor Combined With Antivascular Therapy and Anthracycline/Taxane-based Adjuvant Chemotherapy Versus Anthracycline/Taxane-based Adjuvant Chemotherapy Alone in Patients With Operable Triple-negative Breast CancerRecruitingNCT05862064Phase 3
- Anti-PD-1 Antibody Therapies of Camrelizumab in Combination With Pemetrexed and Carboplatin as First-line Treatment in Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung CancerRecruitingNCT05841472Phase 2
- A Single-arm Clinical Study of HAIC Combined With Apatinib and Camrelizumab in the Treatment of Unresectable MTM HCCRecruitingNCT05839197Phase 2
- Adjuvant Chemotherapy Combined With Camrelizumab for ⅡA -ⅢA NSCLC PatientsRecruitingNCT05825443Phase 2
- Immunotherapy Plus Chemotherapy vs. Chemoradiotherapy for Thoracic Squamous Esophageal CarcinomaNot yet recruitingNCT05821452Phase 2
- Camrelizumab in Combination With Apatinib and Temozolomide as First-line Treatment in Advanced Acral MelanomaRecruitingNCT05789043Phase 3
- Intensified Treatments for Patients With Locally Advanced Nasopharyngeal Carcinoma With Detectable EBV DNA After One Cycle GP Regime Neoadjuvant ChemotherapyRecruitingNCT05772208Phase 3
- Neoadjuvant Camrelizumab and Fluzoparib and Nab-paclitaxel in Early Breast Cancer With HRR Gene MutationRecruitingNCT05761470Phase 2
- FUSCC Refractory TNBC Platform Study (FUTURE2.0)RecruitingNCT05749588Phase 2
- Carrelizumab Combined With Chemotherapy for Adjuvant Therapy of Esophageal Squamous Cell CarcinomaRecruitingNCT05637268Phase 2
- Camrelizumab Combined With Chemoradiotherapy in Advanced Esophageal Cancer.RecruitingNCT05624099Phase 2
- Clinical Efficacy in Neoadjuvant Treatment of Locally Advanced Gastric Cancer With Different ImmunotypesNot yet recruitingNCT05610332Phase 3
- SNF Platform Study of HR+/ HER2-advanced Breast CancerRecruitingNCT05594095Phase 2
- Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant TherapyRecruitingNCT05582499Phase 2
- Fluzoparib Combined With Camrelizumab for Neoadjuvant Treatment of Embryogenic BRCA Mutation HER2 Negative Breast Cancer: an Open, Single Arm, Multicenter StudyRecruitingNCT05576389Phase 2
- A Umbrella Study in R/R PTCL Guided by Molecular SubtypesRecruitingNCT05559008Phase 1/2
- Camrelizumab Plus Anlotinib in Patients With Recurrent Sporadic MMRd Endometrial CancerNot yet recruitingNCT05550558Phase 2
- Targeted or Chemotherapy Combined With Immunotherapy Versus Chemotherapy for PD-1 Inhibitor Refractory R/M NPCRecruitingNCT05549466Phase 2
- Efficacy and Safety of Microwave Ablation Combined With Camrelizumab and Chemotherapy in Patients With Advanced Non-small Cell Lung Cancer: a Multicenter, Open, Prospective StudyNot yet recruitingNCT05532527Not applicable
- Clinical Study of Camrelizumab, Apatinib Mesylate and Nab-paclitaxel Combined With Oxplatin and S-1 in the Neoadjuvant Treatment of Locally Advanced Gastric Cancer With Different GenotypesNot yet recruitingNCT05524974Phase 2
- Camrelizumab Plus Apatinib and Temozolomide as Neoadjuvant in High Risk Acral MelanomaRecruitingNCT05512481Phase 2
- Camrelizumab Combined With Cisplatin in the Treatment of Advanced Cutaneous Squamous Cell CarcinomaRecruitingNCT05490485Phase 2
- Anti-PD-1 Antibody Combined With Autologous DC and NK Cells in the Treatment of Digestive CarcinomaNot yet recruitingNCT05461235Phase 2
- Study of Camrelizumab Plus Apatinib and Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)RecruitingNCT05447702Phase 2
- Whole-target Consolidation Therapy Under Systemic Therapy for Oligometastatic Nasopharyngeal CarcinomaRecruitingNCT05431764Phase 2
- mFOLFOX7 Plus Camrelizumab and Apatinib for Advanced HCCRecruitingNCT05412589Phase 2
- Surufatinib Plus Camrelizumab and AS in First Line Treatment of Advanced Metastatic Pancreatic CancerRecruitingNCT05218889Phase 1/2
- Albumin-bound Paclitaxel Plus Camrelizumab for Advanced Soft Tissue Sarcoma.RecruitingNCT05189483Phase 2
- Study of Camrelizumab in Combination With Apatinib Mesylate Plus Albumin-bound Paclitaxel and Cisplatin as the First Line Treatment of Recurrent or Metastatic, UnresectableHead and Neck Squamous Cell CarcinomaNot yet recruitingNCT05189184Phase 2
- The Neoadjuvant Treatment of Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma.RecruitingNCT05170542Phase 2
- Camrelizumab for the Treatment of Locally Advanced Nasopharyngeal CarcinomaRecruitingNCT05097209Phase 2
- Neoadjuvant Personalized Anti-PD-1 and Anti-VEGFR Therapy in OSCC PatientsRecruitingNCT05069857Phase 2
- Efficiency and Safety of Microwave Ablation Plus Immune Checkpoint Inhibitor for Patients With Multiple Primary Lung Cancer: A Open, Multi-center, Phase II Clinical TrialRecruitingNCT05053802Phase 2
- A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung CancerRecruitingNCT05042375Phase 3
- Hyperbaric Oxygen Therapy Combined Camrelizumab in Patients With Advanced/Metastatic Hepatocellular CarcinomaRecruitingNCT05031949Phase 1
- Camrelizumab and Chemotherapy Combined With Endoscopic Surgery for Recurrent Nasopharyngeal CarcinomaRecruitingNCT05011227Phase 2
- Fluzoparib and Camrelizumab in Treating Patients With R/M NPC That Progressed After First-line ChemotherapyRecruitingNCT04978012Phase 2